FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年11月7日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫 ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年11月6日 FF305 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) | | | 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年11月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）數 | 已發行股份（不包括庫存股份） ...

翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 呈交日期： 2024年11月1日 FF305 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年10月31日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括 ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 普华和顺集团公司 (於開曼群島註冊成立的有限公司) 呈交日期： 2024年10月30日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 變動日期 2024年10月9日 FF305 確認 根據《主板上市規則》第13.25C條 / 《GEM上市規則》第17.27C條，我們在此確認，據我們所知所信，第一章節所述的每項股份發行或庫存股份出售或轉讓已獲發行人董事會正式授權批准，並遵 照所有適用上市規則、法律及其他監管規定進行，並在適用的情況下： | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | ...

FF305 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | | 事件 | 已發行股份（不包括庫存股份）數 目 | | 佔有關事件前的現有已發 行股份（不包括庫存股 份）數目百分比 (註3) | 庫存股份數目 | 每股發行/出售價 (註4) | 已發行股份總數 | | 於下列日期開始時的結存(註1) | 2024年10月28日 | | 1,518,423,098 | | 24,156,000 | | 1,542,579,098 | | 1). 購回股份 (股份被持作庫存股份) | | | -1,000,000 | 0.0659 % | 1,000,000 HKD | 1.076 | | | ...

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 變動日期 2024年10月9日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 01358 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | | | 事件 | | | | | | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 | | ...

PW MEDTECH GROUP LIMITED 普 华 和 顺 集 团 公 司 (於開曼群島註冊成立的有限公司) (股份代號：01358.HK) Khu 中期報告 2024 中國 醫療器械行業的 領先者 我們是領先的醫療器械公司，專注於中國醫療器械行業 中高增長及高利潤率的板塊。我們目前的業務分部為 輸液器、血液淨化產品和再生醫用生物材料，且憑藉 強勁的研發實力及完善的分銷網路穩佔市場領先地位。 目 錄 2 釋義 公司資料 4 管理層討論與分析 5 18 補充資料 23 中期簡明綜合財務報表之審閱報告 24 簡明綜合全面收益表 26 簡明綜合財務狀況表 28 簡明綜合權益變動表 29 簡明綜合現金流量表 30 中期簡明綜合財務報表附註 釋義 | --- | --- | --- | |--------------------------|-------|---------------------------------------------------------------------------------------------------------------------------------- ...

Financial Performance - Revenue increased by 6.1% to approximately RMB 338.4 million compared to RMB 319.0 million in the same period last year[1] - Gross profit rose by 6.1% to approximately RMB 187.6 million from RMB 176.8 million year-on-year[1] - Net profit decreased by 3.3% to approximately RMB 93.6 million, down from RMB 96.9 million in the previous year[1] - Adjusted net profit (non-HKFRS measure) increased by 3.4% to approximately RMB 100.2 million from RMB 96.9 million year-on-year[1] - Basic earnings per share decreased slightly to RMB 4.49 from RMB 4.53 in the same period last year[4] - Total revenue for the first half of 2024 reached RMB 338,417 thousand, compared to RMB 319,015 thousand in the same period of 2023, representing a growth of approximately 6.4%[14] - The company reported a pre-tax profit of RMB 112,301 thousand for the first half of 2024, compared to RMB 108,408 thousand in the same period of 2023, marking an increase of approximately 3.3%[16] - The company reported a net profit attributable to shareholders of RMB 70,219 thousand for the six months ended June 30, 2024, slightly down from RMB 70,976 thousand in the same period of 2023, a decrease of 1.1%[30] - The company reported a net profit attributable to shareholders of RMB 70,219,000 for the six months ended June 30, 2024, compared to RMB 70,976,000 for the same period in 2023, reflecting a decrease of approximately 1.07%[33] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 5,245.6 million, an increase from RMB 5,152.0 million at the end of 2023[5] - Cash and cash equivalents decreased to RMB 1,589.7 million from RMB 1,733.0 million[5] - Total liabilities increased, with current liabilities rising to RMB 222.1 million from RMB 149.3 million[5] - Total non-current liabilities decreased from RMB 183,638,000 to RMB 177,801,000, a reduction of approximately 3%[6] - The net asset value increased slightly from RMB 4,824,985,000 to RMB 4,839,907,000, reflecting a growth of about 0.3%[6] - Total equity rose from RMB 4,824,985,000 to RMB 4,839,907,000, indicating an increase of approximately 0.3%[7] - The company’s total liabilities increased to RMB 405,693 thousand as of June 30, 2024, from RMB 327,064 thousand at the end of 2023, representing a rise of approximately 24%[18] - The company’s total liabilities, including trade and other payables, were RMB 191,815,000 as of June 30, 2024, compared to RMB 130,080,000 as of December 31, 2023, representing an increase of approximately 47.4%[59] Dividends - The company declared an interim dividend of HKD 0.045 per share, down from HKD 0.049 in the previous year[1] - The proposed final dividend for 2023 is HKD 0.0495 per share, totaling HKD 77,212,000, which has been approved by shareholders[34] - The board declared an interim dividend of HKD 0.045 per share for the six months ending June 30, 2024, down from HKD 0.049 per share for the same period in 2023, reflecting a commitment to shareholder returns despite a decrease[121] Research and Development - Research and development expenses decreased to RMB 20.6 million from RMB 23.0 million year-on-year[2] - The company continues to focus on high-end infusion devices, blood purification medical devices, and regenerative medical biomaterials, indicating ongoing investment in R&D[8] - The company is committed to improving its research and development capabilities to ensure long-term competitiveness in the evolving market landscape[76] - Blood purification R&D expenses fell from approximately RMB 10.5 million to about RMB 7.9 million, as the development of related equipment was completed in 2024[92] Market and Business Segments - The revenue from the infusion device segment was RMB 132,618 thousand for the first half of 2024, slightly up from RMB 131,848 thousand in 2023, indicating a marginal increase of 0.5%[16] - The blood purification segment reported revenue of RMB 205,799 thousand in the first half of 2024, up from RMB 187,167 thousand in 2023, reflecting a growth of about 9.9%[16] - The blood purification business achieved a revenue of RMB 205.8 million, representing a 10.0% increase year-on-year, accounting for 60.8% of the group's total revenue during the reporting period[78] - The infusion device business generated revenue of RMB 132.6 million, a 0.6% increase year-on-year, accounting for 39.2% of the total revenue[77] - The regenerative medical biomaterials segment is expected to have high growth potential, driven by increasing demand for medical aesthetics and wound repair, with a focus on product development and commercialization[78] Expenses - Selling and marketing expenses rose by 1.8% to approximately RMB 39.9 million, influenced by increased expenses in the blood purification business[90] - General and administrative expenses increased by 0.8% to approximately RMB 60.3 million, mainly due to higher administrative costs in the blood purification and regenerative medical materials businesses[91] - The blood purification business's general and administrative expenses surged by 19.2% to approximately RMB 28.6 million, driven by professional service fees related to the spin-off and stock-based compensation expenses[91] - Operating profit decreased by 4.1% from approximately RMB 88.2 million to about RMB 84.5 million, impacted by reduced government subsidies and increased share-based compensation expenses[95] Share Buyback and Capital Management - The board announced a share buyback plan with a budget of up to HKD 150 million, reflecting confidence in the company's long-term development and market performance[84] - The company repurchased 4,433,000 ordinary shares during the period, with a total payment of approximately RMB 4,302,000[61] - A total of 23,053,000 shares have been repurchased at a total cost of approximately HKD 26,020,070, with specific monthly repurchase details provided[126] Compliance and Governance - The financial statements were prepared in accordance with Hong Kong Financial Reporting Standards, ensuring compliance and transparency[9] - The company has adopted corporate governance practices in line with the Stock Exchange's guidelines, ensuring effective management and protection of shareholder interests[124] - All directors confirmed compliance with the securities trading standard code during the reporting period, ensuring adherence to regulations[125] Employee and Workforce - The company has approximately 1,302 employees as of June 30, 2024, an increase from 1,244 employees as of December 31, 2023, indicating growth in workforce[120] Risk Management - The company has not hedged any foreign currency fluctuations during the reporting period, exposing it to foreign exchange risks primarily related to USD and HKD[117] - Credit risk is managed through policies that monitor trade and other receivables, with most balances coming from state-owned enterprises or clients with good repayment records[119]